WallStSmart

Kyntra Bio, Inc. (KYNB)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Kyntra Bio, Inc. generates 903% more annual revenue ($7.44M vs $742,000). KYNB leads profitability with a 2199.0% profit margin vs 0.0%. KYNB earns a higher WallStSmart Score of 38/100 (F).

KYNB

Hold

38

out of 100

Grade: F

Growth: 5.3Profit: 4.5Value: 5.0Quality: 5.8
Piotroski: 5/9Altman Z: -20.48

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KYNB2 strengths · Avg: 10.0/10
Profit MarginProfitability
2199.0%10/10

Keeps 2199 of every $100 in revenue as profit

Revenue GrowthGrowth
36.5%10/10

Revenue surging 36.5% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

KYNB4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$27.16M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-13.89M2/10

Negative free cash flow — burning cash

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : KYNB

The strongest argument for KYNB centers on Profit Margin, Revenue Growth. Profitability is solid with margins at 2199.0% and operating margin at -369.1%. Revenue growth of 36.5% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : KYNB

The primary concerns for KYNB are EPS Growth, Market Cap, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

KYNB profiles as a growth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

KYNB is growing revenue faster at 36.5% — sustainability is the question.

KYNB generates stronger free cash flow (-14M), providing more financial flexibility.

Bottom Line

KYNB scores higher overall (38/100 vs 24/100), backed by strong 2199.0% margins and 36.5% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kyntra Bio, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is headquartered in San Francisco, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?